This title appears in the Scientific Report :
2021
Please use the identifier:
http://hdl.handle.net/2128/28689 in citations.
Please use the identifier: http://dx.doi.org/10.2967/jnumed.120.254243 in citations.
Early treatment response assessment using $^{18}$F-FET PET compared to contrast-enhanced MRI in glioma patients after adjuvant temozolomide chemotherapy
Early treatment response assessment using $^{18}$F-FET PET compared to contrast-enhanced MRI in glioma patients after adjuvant temozolomide chemotherapy
The goal of this study was to compare the value of contrast-enhanced MRI and O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) PET for response assessment in glioma patients after adjuvant temozolomide chemotherapy (TMZ). Methods: After biopsy or resection and completion of radiotherapy with concomitant T...
Saved in:
Personal Name(s): | Ceccon, G. |
---|---|
Lohmann, Philipp / Werner, Jan-Michael / Caroline, Tscherpel / Dunkl, Veronika / Stoffels, Gabriele / Rosen, Jurij / Rapp, Marion / Herrlinger, Ulrich / Schäfer, Niklas / Shah, N. J. / Fink, Gereon Rudolf / Langen, Karl-Josef / Galldiks, Norbert (Corresponding author) | |
Contributing Institute: |
Physik der Medizinischen Bildgebung; INM-4 Kognitive Neurowissenschaften; INM-3 |
Published in: | Journal of nuclear medicine, 62 (2021) 7, S. 918-925 |
Imprint: |
New York, NY
Soc.
2021
|
DOI: |
10.2967/jnumed.120.254243 |
PubMed ID: |
33158907 |
Document Type: |
Journal Article |
Research Program: |
Neuroimaging (Dys-)function and Plasticity |
Link: |
Get full text OpenAccess Get full text OpenAccess |
Publikationsportal JuSER |
Please use the identifier: http://dx.doi.org/10.2967/jnumed.120.254243 in citations.
The goal of this study was to compare the value of contrast-enhanced MRI and O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) PET for response assessment in glioma patients after adjuvant temozolomide chemotherapy (TMZ). Methods: After biopsy or resection and completion of radiotherapy with concomitant TMZ, 41 newly diagnosed and histomolecularly characterized glioma patients (glioblastoma, 90%; age range, 20–79 y) were subsequently treated with adjuvant TMZ. MR and 18F-FET PET imaging were performed at baseline and after the second cycle of adjuvant TMZ. We obtained 18F-FET metabolic tumor volumes (MTVs) as well as mean and maximum tumor-to-brain ratios (TBRmean and TBRmax, respectively). Threshold values of 18F-FET PET parameters to predict outcome were established by receiver-operating-characteristic analyses using a median progression-free survival (PFS) of ≥ 9 mo and overall survival (OS) of ≥ 15 mo as reference. MRI response assessment was based on the Response Assessment in Neuro-Oncology (RANO) working group criteria. The predictive value of changes of 18F-FET PET and MRI parameters on survival was evaluated subsequently using univariate and multivariate survival estimates. Results: After 2 cycles of adjuvant TMZ chemotherapy, a treatment-induced reduction of MTV and TBRmax predicted a significantly longer PFS and OS (both P ≤ 0.03; univariate survival analyses) whereas RANO criteria were not significant (P > 0.05). Multivariate survival analysis revealed that TBRmax changes predicted a prolonged PFS (P = 0.012) and changes of MTV a prolonged OS (P = 0.005) independent of O6-methylguanine-DNA-methyltransferase promoter methylation and other strong prognostic factors. Conclusion: Changes of 18F-FET PET parameters appear to be helpful for identifying responders to adjuvant TMZ early after treatment initiation. |